HALOZYME THERAPEUTICS, INC. (HALO) insider trading

By person

14 insiders · 8 transactions

84.8×

Helen I. Torley holds 84.8 times base salary in stock. $84.85M of shares against $1.00M in salary for 2025.

Salary from the company's own proxy. The shares are what Helen I. Torley last reported holding, valued at $110.51, the price Common Stock was last bought or sold at on the open market here, on 8 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Helen Torley

President and CEO

—

$4.42M (8) scheduled

−$4.42M

767,780

0.6765%

$84.85M

+13.5%

Connie Matsui

Director

—

183,035

0.1613%

$20.23M

−5.4%

Michael J. LaBarre

SVP, Chief Technical Officer

—

173,756

0.1531%

$19.20M

0.0%

Matthew L. Posard

Director

—

53,609

0.0472%

$5.92M

−23.3%

Mark Howard Snyder

SVP, Chief Legal Officer

—

49,929

0.0440%

$5.52M

+327.5%

Bernadette Connaughton

Director

—

40,418

0.0356%

$4.47M

−13.6%

Nicole LaBrosse

SVP, Chief Financial Officer

—

38,494

0.0339%

$4.25M

+148.7%

Jeffrey William Henderson

Director

—

36,572

0.0322%

$4.04M

−31.8%

Akiko Moni Miyashita

Director

—

24,937

0.0220%

$2.76M

+20.1%

Barbara Gayle Duncan

Director

—

23,715

0.0209%

$2.62M

+50.5%

Mahesh Krishnan

Director

—

14,462

0.0127%

$1.60M

+122.5%

Cortney Caudill

SVP, Chief Operating Officer

—

7,055

0.0062%

$779.65K

−8.1%

James Paul Lang

Director

—

4,685

0.0041%

$517.74K

—

David A Ramsay

EVP, President, Drug Delivery

—

4,592

0.0040%

$507.46K

—

HALOZYME THERAPEUTICS, INC.

What the insiders did Scheduled selling only

By person